Logo image of SOPH

SOPHIA GENETICS SA (SOPH) Stock Fundamental Analysis

NASDAQ:SOPH - Nasdaq - CH1125843347 - Common Stock - Currency: USD

3  -0.14 (-4.46%)

After market: 3.45 +0.45 (+15%)

Fundamental Rating

3

Taking everything into account, SOPH scores 3 out of 10 in our fundamental rating. SOPH was compared to 37 industry peers in the Health Care Technology industry. SOPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, SOPH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SOPH had negative earnings in the past year.
In the past year SOPH has reported a negative cash flow from operations.
SOPH had negative earnings in each of the past 5 years.
SOPH had a negative operating cash flow in each of the past 5 years.
SOPH Yearly Net Income VS EBIT VS OCF VS FCFSOPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

SOPH's Return On Assets of -40.20% is on the low side compared to the rest of the industry. SOPH is outperformed by 75.68% of its industry peers.
SOPH has a Return On Equity of -62.90%. This is comparable to the rest of the industry: SOPH outperforms 40.54% of its industry peers.
Industry RankSector Rank
ROA -40.2%
ROE -62.9%
ROIC N/A
ROA(3y)-38.14%
ROA(5y)-33.44%
ROE(3y)-53.54%
ROE(5y)-45.3%
ROIC(3y)N/A
ROIC(5y)N/A
SOPH Yearly ROA, ROE, ROICSOPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

SOPH has a Gross Margin of 67.82%. This is in the better half of the industry: SOPH outperforms 70.27% of its industry peers.
SOPH's Gross Margin has been stable in the last couple of years.
SOPH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.64%
GM growth 5Y-0.84%
SOPH Yearly Profit, Operating, Gross MarginsSOPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

4

2. Health

2.1 Basic Checks

SOPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SOPH has been increased compared to 1 year ago.
SOPH has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SOPH is higher compared to a year ago.
SOPH Yearly Shares OutstandingSOPH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
SOPH Yearly Total Debt VS Total AssetsSOPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -1.21, we must say that SOPH is in the distress zone and has some risk of bankruptcy.
SOPH's Altman-Z score of -1.21 is in line compared to the rest of the industry. SOPH outperforms 40.54% of its industry peers.
SOPH has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
SOPH has a Debt to Equity ratio of 0.26. This is comparable to the rest of the industry: SOPH outperforms 56.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z -1.21
ROIC/WACCN/A
WACC5.2%
SOPH Yearly LT Debt VS Equity VS FCFSOPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 3.80 indicates that SOPH has no problem at all paying its short term obligations.
The Current ratio of SOPH (3.80) is better than 83.78% of its industry peers.
SOPH has a Quick Ratio of 3.59. This indicates that SOPH is financially healthy and has no problem in meeting its short term obligations.
SOPH has a better Quick ratio (3.59) than 83.78% of its industry peers.
Industry RankSector Rank
Current Ratio 3.8
Quick Ratio 3.59
SOPH Yearly Current Assets VS Current LiabilitesSOPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.13% over the past year.
The Revenue has been growing slightly by 4.49% in the past year.
The Revenue has been growing by 20.78% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)22.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.84%
Revenue 1Y (TTM)4.49%
Revenue growth 3Y17.23%
Revenue growth 5Y20.78%
Sales Q2Q%4.02%

3.2 Future

SOPH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.87% yearly.
Based on estimates for the next years, SOPH will show a very strong growth in Revenue. The Revenue will grow by 24.98% on average per year.
EPS Next Y6.86%
EPS Next 2Y10.89%
EPS Next 3Y13.87%
EPS Next 5YN/A
Revenue Next Year12.64%
Revenue Next 2Y17.59%
Revenue Next 3Y20.29%
Revenue Next 5Y24.98%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SOPH Yearly Revenue VS EstimatesSOPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M
SOPH Yearly EPS VS EstimatesSOPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SOPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SOPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SOPH Price Earnings VS Forward Price EarningsSOPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SOPH Per share dataSOPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as SOPH's earnings are expected to grow with 13.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.89%
EPS Next 3Y13.87%

More info and screens

0

5. Dividend

5.1 Amount

SOPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOPHIA GENETICS SA

NASDAQ:SOPH (5/6/2025, 8:00:02 PM)

After market: 3.45 +0.45 (+15%)

3

-0.14 (-4.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)03-04 2025-03-04/bmo
Earnings (Next)05-06 2025-05-06/bmo
Inst Owners42.99%
Inst Owner Change-10.99%
Ins Owners5.82%
Ins Owner ChangeN/A
Market Cap200.49M
Analysts83.33
Price Target6.94 (131.33%)
Short Float %0.08%
Short Ratio0.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.41%
Min EPS beat(2)-19.35%
Max EPS beat(2)20.18%
EPS beat(4)2
Avg EPS beat(4)-2.21%
Min EPS beat(4)-34.35%
Max EPS beat(4)24.68%
EPS beat(8)5
Avg EPS beat(8)8.28%
EPS beat(12)8
Avg EPS beat(12)11.08%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.44%
Min Revenue beat(2)-10.93%
Max Revenue beat(2)-1.94%
Revenue beat(4)0
Avg Revenue beat(4)-5.63%
Min Revenue beat(4)-10.93%
Max Revenue beat(4)-1.94%
Revenue beat(8)2
Avg Revenue beat(8)-2.75%
Revenue beat(12)2
Avg Revenue beat(12)-2.72%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)-1.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.11
P/FCF N/A
P/OCF N/A
P/B 1.77
P/tB 2.41
EV/EBITDA N/A
EPS(TTM)-0.95
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0.96
BVpS1.7
TBVpS1.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.2%
ROE -62.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.82%
FCFM N/A
ROA(3y)-38.14%
ROA(5y)-33.44%
ROE(3y)-53.54%
ROE(5y)-45.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.64%
GM growth 5Y-0.84%
F-Score2
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 102.35%
Cap/Sales 13.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.8
Quick Ratio 3.59
Altman-Z -1.21
F-Score2
WACC5.2%
ROIC/WACCN/A
Cap/Depr(3y)130.72%
Cap/Depr(5y)142.16%
Cap/Sales(3y)16.39%
Cap/Sales(5y)15.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.84%
EPS Next Y6.86%
EPS Next 2Y10.89%
EPS Next 3Y13.87%
EPS Next 5YN/A
Revenue 1Y (TTM)4.49%
Revenue growth 3Y17.23%
Revenue growth 5Y20.78%
Sales Q2Q%4.02%
Revenue Next Year12.64%
Revenue Next 2Y17.59%
Revenue Next 3Y20.29%
Revenue Next 5Y24.98%
EBIT growth 1Y4.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.3%
EBIT Next 3Y25.56%
EBIT Next 5Y21.74%
FCF growth 1Y9.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.61%
OCF growth 3YN/A
OCF growth 5YN/A